Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: Role of endothelin-1

American Journal of Pathology

Volumn 159, Issue 5, 2001, Pages 1895-1904

  Suzuki, Yusuke ^a   Lopez Franco, Oscar ^a   Gomez Garre, Dulcenombre ^b   Tejera, Nuria ^a   Gomez Guerrero, Carmen ^a   Sugaya, Takeshi ^c   Bernal, Rosa ^b   Blanco, Julia ^b   Ortega, Luis ^b   Egido, Jesús ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; BOSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; QUINAPRIL; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; GENE EXPRESSION; INTERSTITIAL NEPHRITIS; KIDNEY INJURY; KIDNEY TUBULE EPITHELIUM; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA;

EID: 0035155258     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63036-2     Document Type: Article

References (57)

1. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat
2. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes
3. Prevention of renal injury in diabetic MWF rats by angiotensin II antagonism
4. Effect of antihypertensive therapy on the kidney in patients with diabetes: A metaregression analysis
5. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
6. Renal protection and antihypertensive drugs: Current status
7. Angiotensin II receptor antagonists
8. Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome
9. Reversing glomerular hypertension stabilizes established glomerular injury
10. Vasoactive hormones and renal sclerosis
11. Angiotensin II: A double-edged sword in inflammation
12. Molecular insights into renal interstitial fibrosis
13. The role of tubulointerstitial injury in chronic renal failure
14. Understanding the nature of renal disease progression
15. The role of proteinuria in the progression of chronic renal failure
16. Interstitial nephritis induced by protein-overload proteinuria
17. Angiotensin-converting enzyme is upregulated in the proximal tubules of rats with intense-proteinuria
18. Activation of NFkB in tubular epithelial cells of rats with intense proteinuria. Role of angiotensin II and endothelin-1
19. The pathophysiology of protein-overload proteinuria
20. Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators
21. Renal expression of parathyroid hormone-related protein (PTHrP) and PTH/PTHrP receptor in a rat model of tubulointerstitial damage
22. In vitro autoradiography reveals predominantly AT1 angiotensin II receptors in rat kidney
23. Tissular expression and regulation of type 1 angiotensin II receptor subtypes by quantitative reverse transcriptase-polymerase chain reaction analysis
24. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia
25. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides
26. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?
27. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases
28. 2 receptors in the kidney
29. An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis
30. Quinapril decreases renal endothelin-1 expression and synthesis in a normotensive model of immune-complex nephritis
31. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage
32. Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice
33. Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis
34. Induction of TGF-beta 1 synthesis in D-glucose primed human proximal tubular cells by IL-1 beta and TNF alpha
35. Cytokine interactions promote synergistic fibronectin accumulation by mesangial cells
36. Protein traffic activates NF-kB gene signaling and promotes MCP-1-dependent interstitial inflammation
37. Inhibition of nuclear factor-kappaB activation reduces cortical tubulointerstitial injury in proteinuric rats
38. Interstitial fibrosis in mice with overload proteinuria: Deficiency of TIMP-1 is not protective
39. Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade
40. Mechanism of progression of renal disease: Growth factors and related mechanisms
41. Transcriptional factor-kB (NF-kB) and renal disease
42. Mechanism of angiotensin II-mediated regulation of fibronectin gene in rat vascular smooth muscle cells
43. Stretch activation of jun N-terminal kinase/stress-activated protein kinase in mesangial cells
44. Angiotensin II-induced transactivation of epidermal growth factor receptor regulates fibronectin and transforming growth factor-beta synthesis via transcriptional and posttranscriptional mechanisms
45. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
46. The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin
47. Chronic angiotensin II infusion but not bradykinin blockade abolishes the antiproteinuric response to angiotensin-converting enzyme inhibition in established adriamycin nephrosis
48. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonist
49. Role of angiotensin in the regulation of renal response to proteins
50. AT1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis
51. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor
52. Role of endothelin-1 in angiotensin II-mediated hypertension
53. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: Reversal by ET(A)-receptor antagonist
54. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells
55. Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle
56. Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats
57. Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms